Walgreens: Undervalued Pharma Giant Poised For A Turnaround Amid Cost-Cutting And Activist Investor Potential
Walgreens Boots Alliance is significantly undervalued, trading at low P/E multiples and a 44% discount to its book value, with strong upside potential. New CEO Tim Wentworth's cost-cutting strategy and potential sale of VillageMD are expected to boost cash flow and equity value. Conservative valuation models (DCF, trading comps, exit multiple, GGM) indicate WBA is worth at least $28 per share, making it a strong buy.
Walgreens Stock Slides as Analysts Question Store-Closure Impact
Shares of pharmacy giant Walgreens Boots Alliance (WBA) tumbled on Tuesday after investment bank TD Cowen cut its price target on the stock to $14 from $16.
Why Walgreens Boots Alliance Plunged Again Today
The stock couldn't hold on to its post-earnings rally, as the threat of online competition came to the fore again.
Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy
Walgreens Boots Alliance Inc. NASDAQ: WBA is a leading global retail pharmacy and healthcare company. The stock is trading down 60% from its 52-week high and with a stock performance down 58.5% year-to-date (YTD).
Is Walgreens' Ultra-High-Yield Dividend in Jeopardy Again?
Income investors, beware.
Walgreens: Latest Financials Aren't Comforting Enough
Walgreens Boots Alliance's recent results have sparked investor optimism, providing a lifeline to the sagging stock. The upside sales surprise in Q4 FY24 worked in WBA's favor, but the guidance indicates that sales will remain muted in FY25. The EPS outlook is also disappointing, indicating that WBA's attractive P/E ratio needs to be taken with a pinch of salt and that its big dividends come at a risk.
Is Walgreens Boots Alliance Stock a Buy?
This pharmacy leader could be the comeback story of 2025.
Why Walgreens Boots Alliance Rallied This Week
The company's earnings provided some hope for a turnaround -- but there's a long way to go.
Walgreens Rallies on Store Closure Plan. Is the Stock a Buy Now?
Has Walgreens stock finally put in a bottom?
Why Did Walgreens Stock Rise 20%?
Walgreens recently reported its Q4'24 results (fiscal ends in August), with revenue and earnings exceeding our expectations. The company reported revenue of $37.5 billion and adjusted earnings of $0.39 per share, compared to our estimates of $34.9 billion, and $0.38, respectively.
Walgreens: Cautious Optimism After Earnings (Rating Upgrade)
I initially pitched a short on Walgreens with a price target of $8.35, but the stock reached that target faster than expected. WBA's Q4 earnings call showed a clear commitment to a turnaround, especially with management putting a focus on its core retail pharmacy business and planning to close 1,200 unprofitable stores. I believe WBA stock has bottomed out and am upgrading my rating to Hold, but I'm not willing to upgrade further until a more careful review of the company's 10-K.
This High-Yield Dividend Stock Just Soared 15%. Time to Jump on Board?
Retail pharmacy giant Walgreens Boots Alliance (NASDAQ:WBA) was on a long downward slide long before 2024 began.
